Tianwu Xie1, Habib Zaidi2,3,4,5. 1. Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, CH-1211, Geneva, Switzerland. 2. Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, CH-1211, Geneva, Switzerland. habib.zaidi@hcuge.ch. 3. Geneva Neuroscience Center, Geneva University, Geneva, Switzerland. habib.zaidi@hcuge.ch. 4. Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, Netherlands. habib.zaidi@hcuge.ch. 5. Department of Nuclear Medicine, University of Southern Denmark, DK-500, Odense, Denmark. habib.zaidi@hcuge.ch.
Abstract
PURPOSE: Molecular imaging using PET and hybrid (PET/CT and PET/MR) modalities nowadays plays a pivotal role in the clinical setting for diagnosis and staging, treatment response monitoring, and radiation therapy treatment planning of a wide range of oncologic malignancies. The developing embryo/fetus presents a high sensitivity to ionizing radiation. Therefore, estimation of the radiation dose delivered to the embryo/fetus and pregnant patients from PET examinations to assess potential radiation risks is highly praised. METHODS: We constructed eight embryo/fetus models at various gestation periods with 25 identified tissues according to reference data recommended by the ICRP publication 89 representing the anatomy of the developing embryo/fetus. The developed embryo/fetus models were integrated into realistic anthropomorphic computational phantoms of the pregnant female and used for estimating, using Monte Carlo calculations, S-values of common positron-emitting radionuclides, organ absorbed dose, and effective dose of a number of positron-emitting labeled radiotracers. RESULTS: The absorbed dose is nonuniformly distributed in the fetus. The absorbed dose of the kidney and liver of the 8-week-old fetus are about 47.45 % and 44.76 % higher than the average absorbed dose of the fetal total body for all investigated radiotracers. For 18F-FDG, the fetal effective doses are 2.90E-02, 3.09E-02, 1.79E-02, 1.59E-02, 1.47E-02, 1.40E-02, 1.37E-02, and 1.27E-02 mSv/MBq at the 8th, 10th, 15th, 20th, 25th, 30th, 35th, and 38th weeks of gestation, respectively. CONCLUSION: The developed pregnant female/fetus models matching the ICRP reference data can be exploited by dedicated software packages for internal and external dose calculations. The generated S-values will be useful to produce new standardized dose estimates to pregnant patients and embryo/fetus from a variety of positron-emitting labeled radiotracers.
PURPOSE: Molecular imaging using PET and hybrid (PET/CT and PET/MR) modalities nowadays plays a pivotal role in the clinical setting for diagnosis and staging, treatment response monitoring, and radiation therapy treatment planning of a wide range of oncologic malignancies. The developing embryo/fetus presents a high sensitivity to ionizing radiation. Therefore, estimation of the radiation dose delivered to the embryo/fetus and pregnant patients from PET examinations to assess potential radiation risks is highly praised. METHODS: We constructed eight embryo/fetus models at various gestation periods with 25 identified tissues according to reference data recommended by the ICRP publication 89 representing the anatomy of the developing embryo/fetus. The developed embryo/fetus models were integrated into realistic anthropomorphic computational phantoms of the pregnant female and used for estimating, using Monte Carlo calculations, S-values of common positron-emitting radionuclides, organ absorbed dose, and effective dose of a number of positron-emitting labeled radiotracers. RESULTS: The absorbed dose is nonuniformly distributed in the fetus. The absorbed dose of the kidney and liver of the 8-week-old fetus are about 47.45 % and 44.76 % higher than the average absorbed dose of the fetal total body for all investigated radiotracers. For 18F-FDG, the fetal effective doses are 2.90E-02, 3.09E-02, 1.79E-02, 1.59E-02, 1.47E-02, 1.40E-02, 1.37E-02, and 1.27E-02 mSv/MBq at the 8th, 10th, 15th, 20th, 25th, 30th, 35th, and 38th weeks of gestation, respectively. CONCLUSION: The developed pregnant female/fetus models matching the ICRP reference data can be exploited by dedicated software packages for internal and external dose calculations. The generated S-values will be useful to produce new standardized dose estimates to pregnant patients and embryo/fetus from a variety of positron-emitting labeled radiotracers.
Entities:
Keywords:
Monte Carlo; PET; Pregnant female models; Radiation dosimetry; Simulation
Authors: Helene Benveniste; Joanna S Fowler; William D Rooney; Daryn H Moller; W Walter Backus; Donald A Warner; Pauline Carter; Payton King; Bruce Scharf; David A Alexoff; Yeming Ma; Paul Vaska; David Schlyer; Nora D Volkow Journal: J Nucl Med Date: 2003-09 Impact factor: 10.057
Authors: Lazar Bibin; Jérémie Anquez; Juan Pablo de la Plata Alcalde; Tamy Boubekeur; Elsa D Angelini; Isabelle Bloch Journal: IEEE Trans Biomed Eng Date: 2010-06-21 Impact factor: 4.538
Authors: Tianwu Xie; Pierre-Alexandre Poletti; Alexandra Platon; Christoph D Becker; Habib Zaidi Journal: Eur Radiol Date: 2017-09-08 Impact factor: 5.315
Authors: Nina Petoussi-Henss; Daiki Satoh; Helmut Schlattl; Maria Zankl; Vladimir Spielmann Journal: Radiat Environ Biophys Date: 2021-02-16 Impact factor: 1.925